User profiles for Victoria Harris
 | Victoria HarrisUniversity of Oxford Verified email at phc.ox.ac.uk Cited by 3499 |
[HTML][HTML] What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised …
Background The effectiveness of the COVID-19 vaccination programme depends on mass
participation: the greater the number of people vaccinated, the less risk to the population. …
participation: the greater the number of people vaccinated, the less risk to the population. …
[HTML][HTML] Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label …
…, N Berry, MA Detry, C Saunders, M Fitzgerald, V Harris… - The Lancet, 2021 - thelancet.com
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
[HTML][HTML] Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization
…, A Singapuri, M Sereno, RM Saunders, VC Harris… - Nature medicine, 2023 - nature.com
Post-COVID cognitive deficits, including ‘brain fog’, are clinically complex, with both objective
and subjective components. They are common and debilitating, and can affect the ability to …
and subjective components. They are common and debilitating, and can affect the ability to …
[HTML][HTML] Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of …
Background Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20
million infections and 200 000 deaths each year in resource poor regions of the world. …
million infections and 200 000 deaths each year in resource poor regions of the world. …
[HTML][HTML] Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised …
…, N Berry, M Detry, C Saunders, M Fitzgerald, V Harris… - The Lancet, 2021 - thelancet.com
Background Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties,
has been used to treat COVID-19, but evidence from community randomised trials is …
has been used to treat COVID-19, but evidence from community randomised trials is …
[HTML][HTML] Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective …
…, M Sereno, RM Saunders, VC Harris… - The Lancet …, 2022 - thelancet.com
Background No effective pharmacological or non-pharmacological interventions exist for
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post–COVID-19 study
Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-19)
and lung fibrosis suggest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
and lung fibrosis suggest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled …
…, C Saunders, M Fitzgerald, V Harris… - The Lancet …, 2021 - thelancet.com
Background Doxycycline is often used for treating COVID-19 respiratory symptoms in the
community despite an absence of evidence from clinical trials to support its use. We aimed to …
community despite an absence of evidence from clinical trials to support its use. We aimed to …